RxDoctor Payments Data

Brian Bondurant, MD

Family Medicine · Carbondale, KSNPI 1336566488

Payments from drug & device makers

$726in general payments, 2019–2025

Across 47 payments — averaging $15.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$135
  • Novo Nordisk$125
  • Pfizer$121
  • Lilly USA, LLC$97
  • Boston Scientific$62
  • Boehringer Ingelheim$59
  • plus $128 from 7 others

What the payments were for

  • Food & beverage$71198%
  • Education$152%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$726 in reported general payments places this provider in the 55th percentile of 1,469 family medicine providers in Kansas.

See all family medicine providers in Kansas

Medicare billing

Part B allowed, 2024
$178,120
Medicare patients
496
Services billed
4,274

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide64$70,876
JardianceEmpagliflozin61$52,366
EliquisApixaban54$48,182
MounjaroTirzepatide22$29,896
XareltoRivaroxaban15$23,309
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr33$22,195
JanuviaSitagliptin Phosphate23$19,387
Trelegy ElliptaFluticasone/Umeclidin/Vilanter22$15,769
FarxigaDapagliflozin Propanediol15$13,742
LinzessLinaclotide14$11,791
Xtampza ErOxycodone Myristate15$9,416
OxycontinOxycodone Hcl13$7,043
JanumetSitagliptin Phos/Metformin Hcl12$6,755
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate32$5,805
Incruse ElliptaUmeclidinium Bromide12$4,399

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$125$70,87664 claims
Boehringer IngelheimJardiance$59$52,36661 claims
PfizerEliquis$121$48,18254 claims
GSKAnoro Ellipta, Trelegy Ellipta, Incruse Ellipta$29$42,36367 claims
Lilly USA, LLCMounjaro$97$29,89622 claims
Johnson & JohnsonXarelto$11$23,30915 claims
AstraZenecaFarxiga$135$13,74215 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,469 family medicine providers in Kansas.

Other family medicine in Carbondale

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →